Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 5Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 24Radiotherapy 21Cisplatin 21Cetuximab 13Carboplatin 11Paclitaxel 8Nivolumab 8durvalumab 7Radiotherapy, Intensity-Modulated 6Docetaxel 6Fluorouracil 5Cyclophosphamide 5zalutumumab 4Everolimus 4Amifostine 4spartalizumab 3fludarabine 3epacadostat 3cemiplimab 3Ipilimumab 3Immune Checkpoint Inhibitors 3Gefitinib 3Filgrastim 3Erlotinib Hydrochloride 3Celecoxib 3Capecitabine 3selpercatinib 2palbociclib 2fludarabine phosphate 2bintrafusp alfa protein, human 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Head and Neck Neoplasms × ixabepilone × Clear all
NCT00057850 2013-02-11

BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡